Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.34 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 2/20 | 0.33 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | HTR2B | P41595 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | ERN1 | O75460 | 1/20 | 0.32 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16290833 | 0.89 | SCN9A (0.38) | SCN9ACYP2C9 | |
| SCHEMBL16290971 | 0.86 | SCN9A (0.40) | SCN9A | |
| SCHEMBL16290837 | 0.83 | PDGFRB (0.43) | KITSCN9AHTR2CCYP1A2CYP3A4 | |
| SCHEMBL16296854 | 0.83 | SCN9A (0.37) | KITSCN9AHTR1AHTR2AHTR2C | |
| SCHEMBL19874391 | 0.79 | ALDH1A1 (0.41) | SCN9AABCB1ABCC1CYP3A4TSHR | |
| SCHEMBL16306439 | 0.79 | FYN (0.34) | KITSCN9AABCB1ABCC1CYP2C9 | |
| SCHEMBL27264104 | 0.76 | HTR2A (0.41) | HTR1AHTR2AHTR2CHTR2BACHE | |
| SCHEMBL16290800 | 0.76 | ERN1 (0.36) | SCN9AABCB1ABCC1ERN1FYN | |
| SCHEMBL16293979 | 0.76 | SCN9A (0.39) | SCN9A | |
| SCHEMBL19886442 | 0.76 | TTR (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107531705-B | Bicyclic ketone sulfonamide compounds | 美国安进公司 | 2020-09-18 | — | — | CN | disclosed |
| US-10472356-B2 | Bicyclic ketone sulfonamide compounds | AMGEN INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-10472356-B2 | Bicyclic ketone sulfonamide compounds | AMGEN INC. (US) | 2019-11-12 | — | — | US | disclosed |
| EP-3265465-B1 | BICYCLIC KETONE SULFONAMIDE COMPOUNDS | AMGEN INC (US) | 2019-04-24 | — | — | EP | disclosed |
| EP-3265465-B1 | BICYCLIC KETONE SULFONAMIDE COMPOUNDS | AMGEN INC (US) | 2019-04-24 | — | — | EP | disclosed |
| US-20180051021-A1 | BICYCLIC KETONE SULFONAMIDE COMPOUNDS | AMGEN INC. (US) | 2018-02-22 | — | — | US | disclosed |
| US-20180051021-A1 | BICYCLIC KETONE SULFONAMIDE COMPOUNDS | AMGEN INC. (US) | 2018-02-22 | — | — | US | disclosed |
| US-9776995-B2 | Bicyclic sulfonamide compounds as sodium channel inhibitors | AMGEN INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-9776995-B2 | Bicyclic sulfonamide compounds as sodium channel inhibitors | AMGEN INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-9776995-B2 | Bicyclic sulfonamide compounds as sodium channel inhibitors | AMGEN INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-9212182-B2 | Bicyclic sulfonamide compounds as sodium channel inhibitors | AMGEN INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-9212182-B2 | Bicyclic sulfonamide compounds as sodium channel inhibitors | AMGEN INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-9212182-B2 | Bicyclic sulfonamide compounds as sodium channel inhibitors | AMGEN INC. (US) | 2015-12-15 | — | — | US | disclosed |
| WO-2014201206-A1 | BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS | AMGEN INC. (US) | 2014-12-18 | — | — | WO | disclosed |
| US-20140371201-A1 | BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS | AMGEN INC. | 2014-12-18 | — | — | US | disclosed |
| US-20140371201-A1 | BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS | AMGEN INC. | 2014-12-18 | — | — | US | disclosed |
| WO-2014201173-A1 | BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS | AMGEN INC. (US) | 2014-12-18 | — | — | WO | disclosed |
| WO-2014201173-A1 | BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS | AMGEN INC. (US) | 2014-12-18 | — | — | WO | disclosed |
| US-20140371201-A1 | BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS | AMGEN INC. | 2014-12-18 | — | — | US | disclosed |
| WO-2014201206-A1 | BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS | AMGEN INC. (US) | 2014-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371201-A1 | BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS | SCN7A, TRPV1, TRPV5 | KIT 1849/4885SCN9A 14/4885ABCB1 230/4885 |
| US-10472356-B2 | Bicyclic ketone sulfonamide compounds | TRPV1, TRPA1, KCNJ11 | KIT 3105/4885SCN9A 68/4885ABCB1 311/4885 |
| US-20180051021-A1 | BICYCLIC KETONE SULFONAMIDE COMPOUNDS | TRPV1, TRPA1, KCNJ11 | KIT 3105/4885SCN9A 68/4885ABCB1 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.